Skip to main content
Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Publisher: Bentham Science Publishers

More about this publication?
Volume 14, Number 14, 2008

Articles

Favourites:
ADD

Modulation of the Maturing Gut Barrier and Microbiota: A Novel Target in Allergic Disease
pp. 1368-1375(8)
Authors: Isolauri, E.; Kalliomaki, M.; Laitinen, K.; Salminen, S.

Favourites:
ADD
Favourites:
ADD

Life Under Stress: The Probiotic Stress Response and How it may be Manipulated
pp. 1382-1399(18)
Authors: Corcoran, B. M.; Stanton, C.; Fitzgerald, G.; Ross, R. P.

Favourites:
ADD

Cyclooxygenase Inhibition in Ischemic Brain Injury
pp. 1401-1418(18)
Authors: Candelario-Jalil, Eduardo; Fiebich, Bernd L.

Favourites:
ADD

Cyclooxygenase-1 and -2 in the Different Stages of Alzheimer's Disease Pathology
pp. 1419-1427(9)
Authors: Hoozemans, J. J.M.; Rozemuller, J. M.; van Haastert, E. S.; Veerhuis, R.; Eikelenboom, P.

Favourites:
ADD
Favourites:
ADD

Non Steroidal Anti-Inflammatory Drugs and Neurogenesis in the Adult Mammalian Brain
pp. 1435-1442(8)
Authors: Ajmone-Cat, Maria A.; Cacci, Emanuele; Minghetti, Luisa

Favourites:
ADD

Cyclooxygenase-2 in Synaptic Signaling
pp. 1443-1451(9)
Authors: Yang, Hongwei; Chen, Chu

Favourites:
ADD

COX-2 Inhibition in Schizophrenia and Major Depression
pp. 1452-1465(14)
Authors: Muller, Norbert; Schwarz, Markus J.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content